Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance

OncotypeDx Genomic Prostate Score (GPS) is a 17-gene RNA expression assay intended to help guide treatment decisions for men diagnosed with prostate cancer. The Prostate Imaging-Reporting and Data System version 2 (PI-RADSv2) was developed to standardize the risk stratification of lesions identified on multiparametric prostate MRI. We sought to determine whether these tests are associated with increased risk of biopsy upgrade in men on active surveillance (AS).

Source: The Journal of Urology - September 1, 2018 Category: Urology & Nephrology Authors: Zachary Kornberg, Janet E. Cowan, Antonio C. Westphalen, Matthew R. Cooperberg, June M. Chan, Shoujun Zhao, Katsuto Shinohara, Peter R. Carroll Source Type: research